SciVac Therapeutics Inc.’s acquisition of VBI Vaccines Inc. involved different jurisdictions, accounting standards and stock exchanges.

That presented a series of challenges that the Greenberg Traurig team representing SciVac resolved, including a closing condition that the merged biotechnology companies be listed on Nasdaq.